View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
June 24, 2009

New Zealand Government Authorises Diabecell Diabetes Drug Trials

The New Zealand Ministry of Health has authorised clinical trials for the Living Cell Technologies (LCT) drug for people with insulin-dependent diabetes Diabecell. The authorisation was confirmed following agreements on certain conditions for the trials announced on 19 June 2009.

By cms admin

The New Zealand Ministry of Health has authorised clinical trials for the Living Cell Technologies (LCT) drug for people with insulin-dependent diabetes Diabecell.

The authorisation was confirmed following agreements on certain conditions for the trials announced on 19 June 2009.

One such condition of the new authorisation limits participation in the trial to only patients with poorly controlled (brittle) diabetes.

The remaining conditions are procedural rather than substantive in nature and LCT and the Middlemore Hospital clinical team has requested the Regional Ethics Committee to accept the changes required by the Minister.

LCT CEO Dr Paul Tan said that the company is pleased that the conditions have been finalised. LCT looks forward to commencing the trial within the next two months with the acceptance of the changes by the Ethics Committee.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology